Glenmark Pharmaceuticals Initiates Class II Recall of Atomoxetine Due to N-Nitroso Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall (D-0235-2025) for 80,160 bottles of Atomoxetine Capsules, USP, 60 mg, nationwide. This voluntary action stems from Current Good Manufacturing Practice (CGMP) deviations, specifically N-Nitroso Atomoxetine Impurity exceeding FDA limits. Procurement and regulatory teams must assess supply chain risks and compliance protocols, especially for products sourced globally and susceptible to nitrosamine contamination.
FDA Mandates Class II Recall for Glenmark's Atomoxetine Due to N-Nitroso Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a voluntary Class II recall, designated D-0235-2025, for specific lots of its Atomoxetine Capsules, USP, 60 mg. This critical action, initiated on January 29, 2025, and classified by the FDA on February 20, 2025, impacts 80,160 bottles distributed nationwide within the U.S. The primary reason for this recall is identified as Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Atomoxetine Impurity exceeding the FDA's recommended limit. For procurement directors, this means immediate action is required to identify and quarantine affected inventory. The recall targets Lot Numbers 19234630 (Exp.: 10/2025), 19240528, and 19240529 (Exp.: 1/2026), which are crucial details for inventory management and supply chain adjustments. The affected product, identified by NDC 68462-269-30 for 30-capsule bottles, is a human prescription drug, underscoring the potential patient impact. Regulatory affairs heads must note that a Class II recall indicates a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. This event signals heightened FDA scrutiny on impurity profiles and manufacturing controls.
Market Impact and Supply Chain Vulnerabilities for Atomoxetine
The recall of Glenmark Pharmaceuticals' Atomoxetine Capsules, USP, 60 mg, carries significant implications for market stability and patient access. As a human prescription drug administered orally, Atomoxetine is a critical medication, and a nationwide recall of 80,160 bottles represents a substantial disruption. Business development executives should recognize potential market gaps created by this supply interruption. The product is manufactured for Glenmark Pharmaceuticals Inc., NJ, USA, but explicitly stated as a 'Product of India,' highlighting the complexities and vulnerabilities inherent in global pharmaceutical supply chains. Procurement directors must assess their reliance on Glenmark as a supplier for Atomoxetine and evaluate the robustness of their multi-sourcing strategies. The recall encompasses multiple product NDCs, including 68462-265, 68462-266, 68462-267, 68462-268, 68462-269, 68462-270, and 68462-271, each with various package configurations. This broad scope necessitates a thorough review of all Atomoxetine stock from Glenmark, irrespective of specific dosage or packaging, to ensure compliance and mitigate risk. Supply chain VPs should consider this event a clear signal to diversify their supplier base and enhance due diligence on international manufacturing partners.
Navigating N-Nitroso Impurity Regulations and CGMP Compliance Challenges
The core of Glenmark's recall lies in Current Good Manufacturing Practice (CGMP) deviations leading to N-Nitroso Atomoxetine Impurity levels exceeding FDA recommended limits. This issue is not isolated to Glenmark; N-nitroso compounds, or nitrosamines, have become a significant regulatory focus across the pharmaceutical industry due to their genotoxic and carcinogenic potential. Regulatory affairs heads must interpret this event as a reinforcement of the FDA's stringent expectations for impurity control and process validation. Companies must implement robust risk assessment strategies to identify potential sources of nitrosamine formation, whether from raw materials, solvents, reagents, or degradation pathways during manufacturing and storage. This includes a thorough understanding of the Atomoxetine hydrochloride molecule's susceptibility to such impurities. For procurement teams, this translates into a need for enhanced supplier qualification processes that specifically audit for nitrosamine risk management programs, beyond standard CGMP checks. Business development executives should be aware that companies demonstrating proactive and comprehensive nitrosamine control will gain a competitive advantage in a market increasingly sensitive to these regulatory challenges. This incident underscores that CGMP compliance is an ongoing, evolving requirement, particularly concerning emerging impurity concerns.
Glenmark's Remediation Path and Future Regulatory Scrutiny
With the recall status currently 'Ongoing,' Glenmark Pharmaceuticals Inc., USA, faces significant regulatory scrutiny and a clear mandate for remediation. The firm initiated this voluntary recall via a letter notification, indicating their acknowledgment of the CGMP deviations. However, the FDA will expect a comprehensive investigation into the root cause of the N-Nitroso Atomoxetine Impurity and the underlying CGMP failures. This typically involves a detailed corrective and preventive action (CAPA) plan, which regulatory affairs heads should monitor closely as a benchmark for industry best practices. For supply chain VPs, this means potential long-term impacts on Glenmark's ability to supply the U.S. market, depending on the speed and effectiveness of their remediation efforts. Future FDA inspections are highly probable to verify the implementation and efficacy of these CAPA measures. Business development executives should anticipate that Glenmark's reputation and market share for Atomoxetine may be affected until full compliance is demonstrated and confidence is restored. The ongoing nature of this event necessitates continuous vigilance from all stakeholders regarding Glenmark's progress and any further communications from the FDA, ensuring that procurement decisions are made with the most current regulatory intelligence.
Strategic Implications for Global Chemical and Life Sciences Industry
This Class II recall by Glenmark Pharmaceuticals Inc., USA, for Atomoxetine Capsules serves as a critical case study for the broader global chemical and life sciences industry. Procurement directors must recognize that the 'Product of India' designation for a product distributed nationwide in the U.S. underscores the inherent risks and complexities of international pharmaceutical sourcing. Diversification of the supplier base for critical active pharmaceutical ingredients (APIs) and finished drug products, such as Atomoxetine, becomes paramount to mitigate single-point-of-failure risks. Regulatory affairs heads should proactively review their internal quality systems and those of their contract manufacturing organizations (CMOs) and API suppliers to ensure robust controls against nitrosamine formation and other potential impurities. This includes re-evaluating analytical testing protocols and stability studies. Supply chain VPs should prioritize supplier audits that delve deeply into CGMP adherence, especially for facilities with a history of regulatory challenges or those operating in regions with varying oversight standards. This event highlights that even voluntary recalls can have substantial commercial consequences, impacting product availability, brand reputation, and ultimately, patient trust. Proactive risk management and a commitment to continuous quality improvement are essential for maintaining market access and ensuring business continuity in a highly regulated environment.